PTCT · Ptc Therapeutics, Inc.
$64.78
-0.18 (-0.28%)
At close · Sep 30
View the 10-K filed Feb 19, 2026
Return incl. dividend (before tax)
Customer concentration
— top 4 customers 10% of revenue
4 customers — 10% of revenue (2025)
“During 2025, four of our distributors each accounted for over 10% of our net product sales.”
Market Cap
$5.23B
Shares
83.46M
Volume · Sep 30
1.04M
Avg daily vol (3M)
1.29M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$64.78
Open$65.16
Day$64.15–65.50
52W close$61.37–89.55
Avg vol 30d1.1M
Short int9.7M · 11.7% float · 11.0d
Short vol42%
Last earningsJul 30, 2026
DataJan 2020–Sep 2026
Filing10-Q · Jul 30
Up next
Next earnings call
Oct 24, 2026
Est · unconfirmed
· in 3 wks
filed Jul 30, 2026
call held Jul 30, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$1.01B
Trailing 12 months
Net income (TTM)
−$38.38M
Trailing 12 months
Revenue growth YoY
+101.5%
Year over year
Operating margin
12.5%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-0.8%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$1.64B
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+17.7%
Year over year · more shares
Price change (1Y)
+7.1%
Trailing year
Short interest
11.7%
Latest settlement · 11.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Excellent
Quant / Vol
Moderate
Market backdrop
VIX 16.3 · calm
Equity put/call 0.53
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−10%
below
Price vs 50-day avg
−8%
below
RSI (14)
42
neutral
MACD trend
Positive
52-week position
12%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−8%
trailing
6-month return
−9%
trailing
YTD return
−15%
this year
Relative strength
−21%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $70 › 200d $72 — 200d above 50d
Institutional flow
Accumulating
+8% holders QoQ · +75 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
11.67% of float · ▼ -0.9% MoM · 11.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
384 holders — near 3-yr high, broad support
Squeeze score
70
elevated · 0–100
Fundamentals
Revenue growth
+36%
Y/Y
EPS growth
+264%
Y/Y
Free cash flow
$702.3M
Quant / Vol
risk profile
Volatility
40%
annualized · 1-yr
Max drawdown
−30%
past year
ATR
3.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Jul 30, 2026
Total revenue
· full year 2026
Initiated
$1.18B – $1.28B
prior FY $1.73B
midpoint −28.9% Y/Y
Guided vs delivered
· last 3 settled
Total Revenue Guidance
2024
guided $600M – $850M
$806.78M
In line
Total revenue
2022
guided $700M – $750M
$698.8M
Miss −3.6%
2021 revenue guidance
2021
guided $370M – $390M
$538.59M
Beat +41.7%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−10%
Bearish
Price vs 50-day avg
−8%
Bearish
RSI (14)
42
Neutral
MACD trend
Positive
Bullish
52-week position
12%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $70 › 200d $72 — 200d above 50d
Institutional flow
Accumulating
+8% holders QoQ · +75 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
11.67% of float · ▼ -0.9% MoM · 11.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
384 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $61
Now $65 · 12%
Range high $90
vs 200-day avg -10%
vs 50-day avg -8%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PTCT
this stock
Ptc Therapeutics, Inc.
|
$5.23B | -14.7% | +36.2% | — | 11.7% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +15.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -1.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +553.0% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PTCT | +3.9% | -8.2% | -8.6% | -6.8% | -14.7% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | +4.6% | -8.3% | -20.7% | -6.3% | -26.6% |
Key facts
CIK
1070081
CUSIP
69366J200
13F (30d)
14 filings
11 filers
Visit website
Investor relations